ArticleAntimicrobial agents and chemotherapy2008
In vitro antimycobacterial activities of capuramycin analogues.
Article in Antimicrobial agents and chemotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 78 citations in OpenAlex.
- Review
- The challenges and opportunities of developing small molecule inhibitors of MraY.Annual reports in medicinal chemistry · 2023Article
- Antibiotics and resistance: the two-sided coin of the mycobacterial cell wall.Cell surface (Amsterdam, Netherlands) · 2020Review
- DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors.Journal of medicinal chemistry · 2020Article
- Synergism of the Combination of Traditional Antibiotics and Novel Phenolic Compounds againstPathogens (Basel, Switzerland) · 2020Article
- Structures of Bacterial MraY and Human GPT Provide Insights into Rational Antibiotic Design.Journal of molecular biology · 2020Review
- In vitro synergistic potentials of novel antibacterial combination therapies against Salmonella enterica serovar Typhimurium.BMC microbiology · 2020Article
- Chemical logic of MraY inhibition by antibacterial nucleoside natural products.Nature communications · 2019Article
- Review
- Biosynthetic and Synthetic Strategies for Assembling Capuramycin-Type Antituberculosis Antibiotics.Molecules (Basel, Switzerland) · 2019Review
- Revisiting Anti-tuberculosis Therapeutic Strategies That Target the Peptidoglycan Structure and Synthesis.Frontiers in microbiology · 2019Review
- Mycobacterial cell wall biosynthesis: a multifaceted antibiotic target.Parasitology · 2018Review
- New antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development.The Journal of antibiotics · 2017Review
- Article
- New agents for the treatment of drug-resistant Mycobacterium tuberculosis.Advanced drug delivery reviews · 2016Review
- A biocatalytic approach to capuramycin analogues by exploiting a substrate permissive N-transacylase CapW.Organic & biomolecular chemistry · 2016Article
- The Biosynthesis of Capuramycin-type Antibiotics: IDENTIFICATION OF THE A-102395 BIOSYNTHETIC GENE CLUSTER, MECHANISM OF SELF-RESISTANCE, AND FORMATION OF URIDINE-5'-CARBOXAMIDE.The Journal of biological chemistry · 2015Article
- Antitubercular Nanocarrier Combination Therapy: Formulation Strategies and in Vitro Efficacy for Rifampicin and SQ641.Molecular pharmaceutics · 2015Article
- Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors.The Journal of antibiotics · 2015Article
- Biosynthesis of a water-soluble lipid I analogue and a convenient assay for translocase I.Analytical biochemistry · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Translocase I inhibitor compounds derived from capuramycin demonstrated rapid bactericidal activity against several different mycobacterial species. SQ641 was the most active of the compounds, with a MIC of 0.12 to 8 microg/ml, a postantibiotic effect of 55 h, and interesting synergistic effects with other antitubercular drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.